Home Cart Sign in  
Chemical Structure| 543906-09-8 Chemical Structure| 543906-09-8

Structure of Mavoglurant
CAS No.: 543906-09-8

Chemical Structure| 543906-09-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Mavoglurant is a structurally non-competitive mGlu5 receptor antagonist, has an IC50 of 30 nM in a functional assay with human mGluR5.

Synonyms: AFQ056

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Mavoglurant

CAS No. :543906-09-8
Formula : C19H23NO3
M.W : 313.39
SMILES Code : O=C(N1CC[C@@]2([H])[C@@](C#CC3=CC=CC(C)=C3)(O)CCC[C@@]12[H])OC
Synonyms :
AFQ056
MDL No. :MFCD18633263
InChI Key :ZFPZEYHRWGMJCV-ZHALLVOQSA-N
Pubchem ID :9926832

Safety of Mavoglurant

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Mavoglurant

GPCR

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00414752 Smoking Abstinence Phase 1 Completed - Germany ... More >> Novartis Investigative Site Nuernberg, Germany Less <<
NCT00718341 Fragile X Syndrome Phase 2 Completed - France ... More >> Novartis Investigator Site Bron cedex, France, 69677 Italy Novartis Investigator Site Rome, Italy, 00168 Switzerland Novartis Investigator Site Lausanne, Switzerland, 1011 Less <<
NCT01442259 Mild Moderate|or Severe Renal ... More >>Impairment Less << PHASE1 COMPLETED 2025-08-11 Novartis Investigative Site, K... More >>iel, Germany Less <<
NCT00986414 Parkinson Disease ... More >> Dyskinesias Less << Phase 2 Completed - -
NCT01092065 Parkinson's Disease Phase 2 Completed - United States, California ... More >> The Parkinsons Institute Sunnyvale, California, United States, 94085 United States, Colorado Colorado Neurological Institute Englewood, Colorado, United States, 80113 United States, Indiana Indiana University School of Medicine Indianapolis, Indiana, United States, 46202 United States, Kansas University of Kansas Medical Center - Parkinson's Disease and Movement Disorders Center Kansas City, Kansas, United States, 66160 Less <<
NCT03341715 Familial Alcoholism Vulnerabil... More >>ity Less << Early Phase 1 Not yet recruiting November 30, 2018 United States, Connecticut ... More >> Hartford Hospital Not yet recruiting Hartford, Connecticut, United States, 06102 Contact: Godfrey D Pearlson, MD    203-737-3416    Godfrey.Pearlson@hhchealth.org    Principal Investigator: Godfrey D Pearlson, MD Less <<
NCT00414856 Gastroesophageal Reflux Diseas... More >>e Less << PHASE1 COMPLETED - Novartis Investigative site, B... More >>russels, Belgium|Novartis Investigative site, Paris, France|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative site, Bern, Switzerland Less <<
NCT01482143 Fragile X Syndrome PHASE1 COMPLETED 2025-10-13 Novartis Investigative Site, S... More >>acramento, California, 95817, United States|Novartis Investigative Site, Chicago, Illinois, 60612, United States|Novartis Investigative Site, Nashville, Tennessee, 37232-7548, United States|Novartis Investigative Site, Sant Cugat, Catalunya, 08190, Spain Less <<
NCT00582673 Parkinson's Disease Phase 2 Completed - Germany ... More >> Novartis Investigator Site Dresden, Germany Novartis Investigator Site Kassel, Germany Novartis Investigator Site Leun, Germany Novartis Investigator Site Marburg, Germany Novartis Investigator Site Tuebingen, Germany Less <<
NCT01357239 Fragile X Syndrome Phase 2 Completed - -
NCT01357239 - Completed - -
NCT01385592 Dyskinesias P... More >>arkinson Disease Movement Disorders Parkinsonian Disorders Less << Phase 2 Completed - United States, California ... More >> Novartis Investigative Site Sunnyvale, California, United States, 94089 United States, Colorado Novartis Investigative Site Englewood, Colorado, United States, 80113 Canada, Ontario Novartis Investigative Site London, Ontario, Canada, N6A 4G5 Canada, Quebec Novartis Investigative Site Gatineau, Quebec, Canada, J9J 0A5 France Novartis Investigative Site Clermont-Ferrand Cedex 1, France, 63003 Novartis Investigative Site Lille Cedex, France, 59037 Novartis Investigative Site Pessac, France, 33604 Novartis Investigative Site Poitiers, France, 86021 Germany Novartis Investigative Site Beelitz-Heilstaetten, Germany, 14547 Novartis Investigative Site Berlin, Germany, 12163 Novartis Investigative Site Bochum, Germany, 44791 Novartis Investigative Site Duesseldorf, Germany, 40225 Novartis Investigative Site Kassel, Germany, 34128 Novartis Investigative Site Leipzig, Germany, 04103 Novartis Investigative Site Muenchen, Germany, 80804 Novartis Investigative Site München, Germany, 81675 Novartis Investigative Site Stadtroda, Germany, 07646 Novartis Investigative Site Westerstede/Oldenburg, Germany, 26655 Hungary Novartis Investigative Site Budapest, Hungary, 1085 Novartis Investigative Site Kaposvár, Hungary, 7400 Novartis Investigative Site Szeged, Hungary, H-6725 Italy Novartis Investigative Site Bolzano, BZ, Italy, 39100 Novartis Investigative Site Pisa, PI, Italy, 56126 Novartis Investigative Site Roma, RM, Italy, 00163 Spain Novartis Investigative Site Sant Cugat, Barcelona, Spain, 08190 Novartis Investigative Site Barcelona, Cataluña, Spain, 08036 Novartis Investigative Site Madrid, Spain, 28006 Novartis Investigative Site San Sebastian, Spain, 20014 Less <<
NCT00888004 Parkinson's Disease ... More >> L-dopa Induced Dyskinesia Less << Phase 2 Completed - Germany ... More >> Novartis Investigative Site Dresden, Germany Novartis Investigative Site Kassel, Germany Novartis Investigative Site Leun-Biskirchen, Germany Novartis Investigative Site Marburg, Germany Novartis Investigative Site Tubingen, Germany Less <<
NCT01173731 Parkinson Disease|Dyskinesia, ... More >>Drug-Induced|Levodopa Less << PHASE2 COMPLETED 2025-10-13 Novartis Investigative Site, S... More >>unnyvale, California, 94089, United States|Novartis Investigative Site, Englewood, Colorado, 80113, United States|Novartis Investigative Site, Indianapolis, Indiana, 46202, United States|Novartis Investigative Site, Heidelberg, Victoria, 3081, Australia|Novartis Investigative Site, Parkville, Victoria, 3050, Australia|Novartis Investigative Site, Prahran, Victoria, 3181, Australia|Novartis Investigative Site, Ottawa, Ontario, K1G 4G3, Canada|Novartis Investigative Site, Gatineau, Quebec, J9J 0A5, Canada|Novartis Investigative Site, Greenfield Park, Quebec, J4V 2J2, Canada|Novartis Investigative Site, Clermont-Ferrand Cedex 1, 63003, France|Novartis Investigative Site, Lille Cedex, 59037, France|Novartis Investigative Site, Pessac, 33604, France|Novartis Investigative Site, Bochum, 44791, Germany|Novartis Investigative Site, Dresden, 01307, Germany|Novartis Investigative Site, Kassel, 34128, Germany|Novartis Investigative Site, Marburg, 35039, Germany|Novartis Investigative Site, Muenchen, 80804, Germany|Novartis Investigative Site, Stadtroda, 07646, Germany|Novartis Investigative Site, Tuebingen, 72076, Germany|Novartis Investigative Site, Lido di Camaiore, LU, 55041, Italy|Novartis Investigative Site, Roma, RM, 00163, Italy|Novartis Investigative Site, Napoli, 80131, Italy Less <<
NCT01019473 Huntington's Disease ... More >> Chorea Less << Phase 2 Terminated - Germany ... More >> Novartis Investigator Site Berlin, Germany Novartis Investigator Site Bochum, Germany Novartis Investigator Site Munster, Germany Novartis Investigator Site Taufkirchen, Germany Novartis Investigator Site Tubingen, Germany Novartis Investigator Site Ulm, Germany United Kingdom Novartis Investigator Site Birmingham, United Kingdom Novartis Investigator Site Cardiff, United Kingdom Novartis Investigator Site Manchester, United Kingdom Novartis Investigator Site Oxford, United Kingdom Less <<
NCT03242928 Cocaine-related Disorder Phase 2 Recruiting January 8, 2020 Argentina ... More >> Novartis Investigative Site Recruiting Buenos Aires, Argentina, 1058 Novartis Investigative Site Recruiting Buenos Aires, Argentina, 4634 Novartis Investigative Site Recruiting Buenos Aires, Argentina, C1405B0A Spain Novartis Investigative Site Recruiting San Juan de Alicante, Alicante, Spain, 03550 Novartis Investigative Site Recruiting Barcelona, Catalunya, Spain, 08003 Novartis Investigative Site Recruiting Barcelona, Spain, 08036 Switzerland Novartis Investigative Site Recruiting Basel, Switzerland, 4025 Novartis Investigative Site Recruiting Zuerich, Switzerland, 8001 Less <<
NCT01348087 Fragile X Syndrome PHASE2 TERMINATED 2025-09-14 Novartis Investigative Site, P... More >>hoenix, Arizona, 85006, United States|Novartis Investigative Site, Sacramento, California, 95817, United States|Novartis Investigative Site, Decatur, Georgia, 30033, United States|Novartis Investigative Site, Chicago, Illinois, 60612, United States|Novartis Investigative Site, Indianapolis, Indiana, 46202, United States|Novartis Investigative Site, Boston, Massachusetts, 02115, United States|Novartis Investigative Site, Omaha, Nebraska, 68198-5575, United States|Novartis Investigative Site, Staten Island, New York, 10314, United States|Novartis Investigative Site, Media, Pennsylvania, 19063, United States|Novartis Investigative Site, Nashville, Tennessee, 37212, United States|Novartis Investigative Site, Ryde, New South Wales, 2112, Australia|Novartis Investigative Site, Waratah, New South Wales, 2298, Australia|Novartis Investigative Site, Caulfield, Victoria, 3161, Australia|Novartis Investigative Site, Brampton, Ontario, L6Y 1M5, Canada|Novartis Investigative Site, Sherbrooke, Quebec, J1H 5N4, Canada|Novartis Investigative Site, Glostrup, 2600, Denmark|Novartis Investigative Site, Bron Cedex, 69677, France|Novartis Investigative Site, Paris, 75013, France|Novartis Investigative Site, Berlin, 12203, Germany|Novartis Investigative Site, Mainz, 55131, Germany|Novartis Investigative Site, Tübingen, 72076, Germany|Novartis Investigative Site, Würzburg, 97070, Germany|Novartis Investigative Site, Genova, GE, 16147, Italy|Novartis Investigative Site, Malaga, Andalucia, 29010, Spain|Novartis Investigative Site, Sant Cugat, Catalunya, 08190, Spain|Novartis Investigative Site, Lausanne, 1011, Switzerland|Novartis Investigative Site, Zurich, 8091, Switzerland|Novartis Investigative Site, Edinburgh, EH10 5HF, United Kingdom Less <<
NCT01253629 Fragile X Syndrome Phase 2 Completed - -
NCT01433354 Fragile X Syndrome PHASE2|PHASE3 TERMINATED 2025-09-14 Novartis Investigative Site, S... More >>acramento, California, 95817, United States|Novartis Investigative Site, Decatur, Georgia, 30033, United States|Novartis Investigative Site, Chicago, Illinois, 60612, United States|Novartis Investigative Site, Boston, Massachusetts, 02115, United States|Novartis Investigative Site, Omaha, Nebraska, 68198-5575, United States|Novartis Investigative Site, Staten Island, New York, 10314, United States|Novartis Investigative Site, Nashville, Tennessee, 37212, United States|Novartis Investigative Site, Westmead, New South Wales, 2145, Australia|Novartis Investigative Site, Parkville, Victoria, 3052, Australia|Novartis Investigative Site, Bruxelles, 1200, Belgium|Novartis Investigative Site, Leuven, 3000, Belgium|Novartis Investigative Site, Glostrup, 2600, Denmark|Novartis Investigative Site, Bron Cedex, 69677, France|Novartis Investigative Site, Mainz, 55131, Germany|Novartis Investigative Site, München, 80639, Germany|Novartis Investigative Site, Tübingen, 72076, Germany|Novartis Investigative Site, Würzburg, 97070, Germany|Novartis Investigative Site, Ramat Gan, 52621, Israel|Novartis Investigative Site, Genova, GE, 16147, Italy|Novartis Investigative Site, Padova, 35128, Italy|Novartis Investigative Site, Rotterdam, 3015 CE, Netherlands|Novartis Investigative Site, Málaga, Andalucia, 29009, Spain|Novartis Investigative Site, Sabadell, Barcelona, 08208, Spain|Novartis Investigative Site, Sant Cugat, Catalu?a, 08190, Spain|Novartis Investigative Site, Sp?nga, 16374, Sweden|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, Zurich, 8091, Switzerland|Novartis Investigative Site, Edinburgh, EH10 5HF, United Kingdom Less <<
NCT01456663 Hepatic Impairment PHASE1 COMPLETED 2025-07-12 Novartis Investigative Site, O... More >>rlando, Florida, 32809, United States|Novartis Investigative Site, Berlin, 10117, Germany|Novartis Investigative Site, Balatonfured, 8230, Hungary Less <<
NCT01491529 Dyskinesias P... More >>arkinson Disease Movement Disorders Parkinsonian Disorders Anti-Dyskinesia Agents Less << Phase 2 Completed - -
NCT01348087 Fragile X Syndrome PHASE2 TERMINATED 2025-09-14 Novartis Investigative Site, P... More >>hoenix, Arizona, 85006, United States|Novartis Investigative Site, Sacramento, California, 95817, United States|Novartis Investigative Site, Decatur, Georgia, 30033, United States|Novartis Investigative Site, Chicago, Illinois, 60612, United States|Novartis Investigative Site, Indianapolis, Indiana, 46202, United States|Novartis Investigative Site, Boston, Massachusetts, 02115, United States|Novartis Investigative Site, Omaha, Nebraska, 68198-5575, United States|Novartis Investigative Site, Staten Island, New York, 10314, United States|Novartis Investigative Site, Media, Pennsylvania, 19063, United States|Novartis Investigative Site, Nashville, Tennessee, 37212, United States|Novartis Investigative Site, Ryde, New South Wales, 2112, Australia|Novartis Investigative Site, Waratah, New South Wales, 2298, Australia|Novartis Investigative Site, Caulfield, Victoria, 3161, Australia|Novartis Investigative Site, Brampton, Ontario, L6Y 1M5, Canada|Novartis Investigative Site, Sherbrooke, Quebec, J1H 5N4, Canada|Novartis Investigative Site, Glostrup, 2600, Denmark|Novartis Investigative Site, Bron Cedex, 69677, France|Novartis Investigative Site, Paris, 75013, France|Novartis Investigative Site, Berlin, 12203, Germany|Novartis Investigative Site, Mainz, 55131, Germany|Novartis Investigative Site, Tübingen, 72076, Germany|Novartis Investigative Site, Würzburg, 97070, Germany|Novartis Investigative Site, Genova, GE, 16147, Italy|Novartis Investigative Site, Malaga, Andalucia, 29010, Spain|Novartis Investigative Site, Sant Cugat, Catalunya, 08190, Spain|Novartis Investigative Site, Lausanne, 1011, Switzerland|Novartis Investigative Site, Zurich, 8091, Switzerland|Novartis Investigative Site, Edinburgh, EH10 5HF, United Kingdom Less <<
NCT01433354 Fragile X Syndrome PHASE2|PHASE3 TERMINATED 2025-09-14 Novartis Investigative Site, S... More >>acramento, California, 95817, United States|Novartis Investigative Site, Decatur, Georgia, 30033, United States|Novartis Investigative Site, Chicago, Illinois, 60612, United States|Novartis Investigative Site, Boston, Massachusetts, 02115, United States|Novartis Investigative Site, Omaha, Nebraska, 68198-5575, United States|Novartis Investigative Site, Staten Island, New York, 10314, United States|Novartis Investigative Site, Nashville, Tennessee, 37212, United States|Novartis Investigative Site, Westmead, New South Wales, 2145, Australia|Novartis Investigative Site, Parkville, Victoria, 3052, Australia|Novartis Investigative Site, Bruxelles, 1200, Belgium|Novartis Investigative Site, Leuven, 3000, Belgium|Novartis Investigative Site, Glostrup, 2600, Denmark|Novartis Investigative Site, Bron Cedex, 69677, France|Novartis Investigative Site, Mainz, 55131, Germany|Novartis Investigative Site, München, 80639, Germany|Novartis Investigative Site, Tübingen, 72076, Germany|Novartis Investigative Site, Würzburg, 97070, Germany|Novartis Investigative Site, Ramat Gan, 52621, Israel|Novartis Investigative Site, Genova, GE, 16147, Italy|Novartis Investigative Site, Padova, 35128, Italy|Novartis Investigative Site, Rotterdam, 3015 CE, Netherlands|Novartis Investigative Site, Málaga, Andalucia, 29009, Spain|Novartis Investigative Site, Sabadell, Barcelona, 08208, Spain|Novartis Investigative Site, Sant Cugat, Catalu?a, 08190, Spain|Novartis Investigative Site, Sp?nga, 16374, Sweden|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, Zurich, 8091, Switzerland|Novartis Investigative Site, Edinburgh, EH10 5HF, United Kingdom Less <<
NCT01813019 - Terminated(Study was premature... More >>ly terminated at the time of the first Interim Analysis (IA) as the study did not meet its primary efficacy objective.) Less << - -
NCT02920892 Fragile X Syndrome Phase 2 Recruiting July 1, 2020 United States, California ... More >> Univeristy of California - Davis Recruiting Davis, California, United States, 95817 Contact: Erika Bickel    916-703-0281    esbickel@ucdavis.edu    Principal Investigator: Randi Hagerman, MD          United States, Colorado Children's Hospital of Colorado Recruiting Denver, Colorado, United States, 80045 Contact: Nanastasia Welnick    720-777-8606    Nanastasia.Welnick@childrenscolorado.org    Contact: Gina Vanderveen    7207775514    Gina.VanderVeen@childrenscolorado.org    Principal Investigator: Nicole Tartaglia, MD          United States, District of Columbia Children's National Medical Center Recruiting Washington, District of Columbia, United States, 20010 Contact: Grace Tom    202-476-6551    gtom@childrensnational.org    Principal Investigator: Andrea Gropman, MD          United States, Georgia Emory University Not yet recruiting Atlanta, Georgia, United States, 30033 Contact: Jean Luan McColl    404-778-8619       Principal Investigator: Amy Talboy, MD          United States, Illinois Rush University Medical Center Recruiting Chicago, Illinois, United States, 60612 Contact: Katherine Friedmann, RN    312-942-9841       Contact: Anna DeSonia    312-942-7250    Anna_M_DeSonia@rush.edu    United States, Massachusetts Boston Children's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Kate Pawlowski    857-218-5472    neuronext@childrens.harvard.edu    Principal Investigator: Lisa Prock, MD, MPH          United States, Missouri St Louis Children's Hospital (Washington University School of Medicine) Recruiting Saint Louis, Missouri, United States, 63110 Contact: Kathleen Black    314-362-7166    black290@wustl.edu    Contact: Mangesha Teshome    314-77-8420    teshomem@wustl.edu    Principal Investigator: Bryan McGill, MD, PhD          United States, New York Columbia University - New York Presbyterian Recruiting New York, New York, United States, 10605 Contact: Elizabeth Aaron    914-997-5242    ea2781@cumc.columbia.edu    Principal Investigator: Jeremy Veenstra-VanderWeele, MD          United States, Ohio Cincinnati Children's Hospital Medical Center Recruiting Cincinnati, Ohio, United States, 45229 Contact: Nicole McCoy    513-636-0526    nicole.mccoy@cchmc.org,    Contact: Hilary Rosselot    513-636-4134    hilary.rosselot@cchmc.org    Principal Investigator: Craig Erickson, MD          Nationwide Children's Hospital Recruiting Columbus, Ohio, United States, 43205 Contact: Rachel Heffern    614-722-4684    rachel.heffern@nationwidechildrens.org    Principal Investigator: Lenora Lehwald, MD          United States, Pennsylvania Children's Hospital of Pittsburgh Recruiting Pittsburgh, Pennsylvania, United States, 15213 Contact: Christine Amity    412-383-7549    amitycl@upmc.edu    Principal Investigator: Robin Filipink, MD          United States, Tennessee Vanderbilt University Medical Center Recruiting Nashville, Tennessee, United States, 37232 Contact: Rebecca Kaiser    615-343-4590    Rebecca.kaiser@vanderbilt.edu    Principal Investigator: Angela Maxwell-Horn, MD          United States, Texas Children's Health - Children's Medical Center (UTSW) Not yet recruiting Dallas, Texas, United States, 75390 Contact: Deanna Meyer    214-648-2926    Deanna.Myer@UTSouthwestern.edu    Principal Investigator: Sailaja Golla, MBBS Less <<
NCT01491932 Dyskinesias|Parkinson Disease|... More >>Movement Disorders|Parkinsonian Disorders|Anti-Dyskinesia Agents Less << PHASE2 COMPLETED 2025-10-13 Novartis Investigative Site, E... More >>nglewood, Colorado, 80113, United States|Novartis Investigative Site, Kansas City, Kansas, 66160, United States|Novartis Investigative Site, Milwaukee, Wisconsin, 53233, United States|Novartis Investigative Site, Innsbruck, A-6020, Austria|Novartis Investigative Site, Linz, A-4020, Austria|Novartis Investigative Site, Vienna, A-1220, Austria|Novartis Investigative Site, London, Ontario, N6A 4G5, Canada|Novartis Investigative Site, Clermont-Ferrand Cedex 1, 63003, France|Novartis Investigative Site, Lille Cedex, 59037, France|Novartis Investigative Site, Pessac, 33604, France|Novartis Investigative Site, Beelitz-Heilstaetten, 14547, Germany|Novartis Investigative Site, Berlin, 12163, Germany|Novartis Investigative Site, Bochum, 44791, Germany|Novartis Investigative Site, Kassel, 34128, Germany|Novartis Investigative Site, Leipzig, 04103, Germany|Novartis Investigative Site, München, 81675, Germany|Novartis Investigative Site, Stadtroda, 07646, Germany|Novartis Investigative Site, Westerstede/Oldenburg, 26655, Germany|Novartis Investigative Site, Kaposvár, 7400, Hungary|Novartis Investigative Site, Szeged, H-6725, Hungary|Novartis Investigative Site, Brescia, BS, 25123, Italy|Novartis Investigative Site, Pisa, PI, 56126, Italy|Novartis Investigative Site, Roma, RM, 00163, Italy|Novartis Investigative Site, Roma, RM, 00179, Italy|Novartis Investigative Site, Bratislava, 82606, Slovakia|Novartis Investigative Site, Bratislava, 83305, Slovakia|Novartis Investigative Site, Barcelona, Catalunya, 08036, Spain|Novartis Investigative Site, Sant Cugat, Catalunya, 08190, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, 20014, Spain|Novartis Investigative Site, Barcelona, 08025, Spain|Novartis Investigative Site, Madrid, 28006, Spain|Novartis Investigative Site, Bern, 3010, Switzerland Less <<
NCT03327792 Alcohol Drinking Phase 1 Recruiting June 7, 2019 United States, Connecticut ... More >> CMHC, Substance Abuse Center Recruiting New Haven, Connecticut, United States, 06519 Contact: Dana A Cavallo, Ph.D.    203-974-7607    dana.cavallo@yale.edu    Contact: Nick Franco    2039747607    nicholas.franco@yale.edu    Principal Investigator: Suchitra Krishnan-Sarin, Ph.D. Less <<
NCT01813019 Patient Diagnosed With OCD and... More >> Resistant to SSRI Treatment Failed SSRI Over 12 Weeks at Appropriate Doses Less << Phase 2 Terminated(Study was premature... More >>ly terminated at the time of the first Interim Analysis (IA) as the study did not meet its primary efficacy objective.) Less << - United States, California ... More >> Novartis Investigative Site San Diego, California, United States, 92103 United States, Massachusetts Novartis Investigative Site Watertown, Massachusetts, United States, 02472 United States, New York Novartis Investigative Site Brooklyn, New York, United States, 11229 Bulgaria Novartis Investigative Site Burgas, Bulgaria, 8000 Novartis Investigative Site Pazardzhik, Bulgaria, 4400 Novartis Investigative Site Sofia, Bulgaria, 1431 Novartis Investigative Site Sofia, Bulgaria, 1632 Novartis Investigative Site Varna, Bulgaria, 9020 Czech Republic Novartis Investigative Site Strakonice, Czech Republic, 386 29 Germany Novartis Investigative Site Berlin, Germany, 10117 Novartis Investigative Site Freiburg, Germany, 79106 Novartis Investigative Site Muenchen, Germany, 80336 Novartis Investigative Site Nürnberg, Germany, 90419 Novartis Investigative Site Ulm, Germany, 89081 Switzerland Novartis Investigative Site Bern, Switzerland, 3010 Less <<
NCT06136195 Alcohol Consumption|Heavy Drin... More >>ker|Alcohol Use Disorder (AUD) Less << PHASE2 RECRUITING 2026-05-31 Connecticut Mental Health Cent... More >>er (SAC and SATU), New Haven, Connecticut, 06511, United States|Yale New Haven Hospital, New Haven, Connecticut, 06512, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.19mL

0.64mL

0.32mL

15.95mL

3.19mL

1.60mL

31.91mL

6.38mL

3.19mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories